4D MOLECULAR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.25 USD | -2.18% |
|
-4.15% | +19.69% |
Presenter SpeechSalveen Richter (Analysts)Good morning, everyone, and thank you for joining us...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
24.25
USD
Average target price
54.22
USD
Spread / Average Target
+123.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.69% | 1.24B | |
| +4.09% | 43.84B | |
| +46.51% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- FDMT Stock
- News 4D Molecular Therapeutics, Inc.
- Transcript : 4D Molecular Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 08
